10 September 2022
Belpharma S.A., who acquired Beromun® from Boehringer Ingelheim in 2017, has renewed the exclusive distribution rights with EarlyHealth Group. This covers the rights to develop, manage, organize and structure the import process within the following markets, both for registered and unregistered, to ensure Beromun® is received by patients at the accredited sites : Argentina, Bahrain, Brazil, Chile, Colombia, Costa Rica, Ecuador, Kuwait, Mexico, Oman, Panama, Paraguay, Peru, Qatar, Saudi Arabia, Turkey, United Arab Emirates and Uruguay.
Beromun® is used in patients with soft-tissue sarcoma of the limbs, together with melphalan, using a technique called “isolated-limb perfusion” (ILP): both medicines are injected into the limb while the blood circulation in the limb is kept isolated from the rest of the body.
We are delighted to continue our partnership with Belpharma, and carrying on our mission to ensure patients receive access to novel medicinal products for the treatment of rare and orphan diseases.
